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ABSTRACT 
Background:  Polysubstance use is associated with adverse health and social outcomes, but 1 
few studies have investigated whether these associations differ between individuals engaged 2 
in different patterns of illicit drug and non-prescription medication use.  3 
Methods:  Latent Class Analysis (LCA) was used to identify patterns of drug use in the 4 
Global Drug Survey, a purposive sample collected in late 2012 and surveyed using an online 5 
questionnaire including past-year drug use, sociodemographics, mental illness, involvement 6 
in violence and sexual behaviour.  The sample analyzed (N=14,869; median age 27 years; 7 
68.5% male) included those residing in the UK (N=5,869), Australia (N=6,313), and the USA 8 
(N=2,687). 9 
Results:  LCA of cannabis, ecstasy, cocaine, stimulants, nitrous, ketamine, benzodiazepines, 10 
and opioid pain-killer use identified six classes: no polysubstance use (Class 1, 49.1%); 11 
cannabis and ecstasy (Class 2, 23.6%); all illicit drugs (Class 3, 9.4%); ecstasy and cocaine 12 
(Class 4, 8.3%); cannabis and medication (Class 5, 5.9%); all drugs (Class 6, 3.8%).  13 
Participants diagnosed with anxiety were most likely to belong to Class 5 (OR 2.66, 95% CI 14 
2.10-3.38).  Violent behaviour was most strongly associated with Class 6 membership (OR 15 
1.9, 95% CI 1.36-2.64).  Sexual risk-taking also predicted membership of this class (OR 5.79, 16 
95% CI 4.66-7.18), and Class 4 (OR 4.41, 95% CI 3.57-5.43).   17 
Conclusions:  Five heterogeneous groups of polysubstance users were identified in this 18 
international sample covering the UK, Australia, and USA.  Anxiety disorders were 19 
associated with medication and cannabis use, while high-risk behaviours predicted use of 20 
cocaine and ecstasy, or wide-ranging polysubstance use including ketamine and medications.      21 
 22 
 23 
 24 
 25 
 26 
 27 
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1 - INTRODUCTION 28 
Polysubstance use, the use of multiple substances within a given time frame, is 29 
associated with increased risk of acute toxicity including overdose, adverse psychological 30 
experiences and engaging in high-risk behaviours such as violence and unprotected sex [1-3].  31 
Although polysubstance use patterns are diverse [4-6], only a few studies have explored 32 
whether risk behaviours and health outcomes are the same across differing polysubstance use 33 
patterns.  These studies have used latent class analysis (LCA), a technique for identifying 34 
subgroups, to characterize drug use patterns and their association with other participant 35 
attributes.  LCA studies of general population samples have demonstrated that polysubstance 36 
use is associated with higher levels of drug dependence [6], mental illness [5-7], and suicidal 37 
thoughts and attempts [6, 8].  Polysubstance users also have a higher likelihood of poor 38 
physical health [7, 9, 10], sexually transmitted infections [5], being incarcerated [5], and 39 
having experienced childhood sexual, physical, or emotional abuse [6, 11]. 40 
However, few LCA studies have explored patterns of illicit polysubstance use in 41 
detail. In many studies, individuals using drugs other than alcohol, tobacco, or cannabis were 42 
combined in one group [7, 10, 12, 13], or sometimes two, with the latter group simply 43 
characterised as using a greater number of drugs [8, 11, 14].  This limited capacity to 44 
distinguish different types of polysubstance use is due to multiple factors, but the prevalence 45 
of illicit drug use is a key driver.  Small samples or representative general population 46 
samples, particularly with mostly adolescent participants, will contain relatively few 47 
individuals who have used multiple illicit drugs.  Including alcohol and tobacco use in the 48 
LCA polysubstance model, especially in these types of samples, produces a model which is 49 
dominated by use of these drugs due to their comparatively high prevalence, making it 50 
difficult to identify variation in illicit drug use.   51 
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LCA excluding alcohol and tobacco use and using large adult samples (>5000 52 
participants) have identified distinct groups of polysubstance users characterised by different 53 
patterns of illicit drug use.  Lynskey et al. [6] identified four different patterns of lifetime 54 
illicit polysubstance use in a LCA of an Australian adult twin sample.  Two groups, 55 
characterised by sedative and opioid use and by high use of all substances, had approximately 56 
two-fold greater odds of major depressive disorder (MDD), suicidal ideation, and suicide 57 
attempts compared to other polysubstance groups.  These two patterns of use have also been 58 
associated with MDD and generalized anxiety disorder (GAD) in large-scale studies of adults 59 
from the USA where substance use was defined using measures of abuse/dependence [15], 60 
and past-year use in those meeting criteria for alcohol dependence [5].  Additionally, these 61 
studies found an association between use of a wide range of illicit drugs and conduct disorder 62 
[6] or “deviant behaviour” (attacking others, selling illegal drugs, or stealing) [5].  These 63 
studies have demonstrated that patterns of illicit drug use are more complex than a simple 64 
increase in the number of drugs used, as are the associations between polysubstance use and 65 
mental health.  However, these studies were based on data collected primarily in adults and 66 
prior to 2008; it is unclear whether the same patterns of use would be observed in more recent 67 
samples, particularly participants who use drugs that have only recently seen an increase in 68 
use, such as ketamine. 69 
We build on this research using data from the 2012 Global Drug Survey (GDS; 70 
www.globaldrugsurvey.com) to conduct a LCA of past year illicit and prescription drug use 71 
in a large sample of teenagers and adults.  This survey provides a novel perspective on 72 
polysubstance use as it has collected very large samples with higher rates of substance use 73 
than the general population, facilitating the investigation of polysubstance use involving 74 
drugs for which the population prevalence of use is relatively low.  GDS conducts annual 75 
anonymous online surveys of drug and alcohol use using research tools based on work 76 
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conducted by the group over the last decade [16-24].  Using these data, we first characterised 77 
patterns of self-reported drug use as the subgroups in the GDS sample to see if they differed 78 
from previous large-scale LCA studies.  We then explored associations between patterns of 79 
drug use and socio-demographic characteristics, mental health problems, and high-risk 80 
behaviours, particularly whether the direction or strength of these associations varied 81 
between polysubstance groups. 82 
2 - METHODS 83 
2.1 - Sample 84 
GDS is an anonymous, annual online survey of drug use promoted in partnership with 85 
the dance music magazine Mixmag, the Guardian and Fairfax Media, and also distributed 86 
through Facebook, Twitter, social news website Reddit, and drug discussion forums.  The 87 
sample is non-random and should not be seen as representative of drug users.  Between 15th 88 
November 2012 and 2nd January 2013 22,289 responses were received from participants 89 
resident in 125 countries [25]. Due to the sensitive nature of the survey IP addresses were not 90 
collected, consequently multiple entries from one IP address could not be eliminated.  91 
However, it is unlikely that participants completed the survey multiple times due to the 92 
substantial time commitment required and absence of material incentives.  No identical sets 93 
of responses were identified.  In order to use a relatively homogeneous sample the analyses 94 
reported here were limited to residents of the United Kingdom (UK), Australia, and the 95 
United States of America (USA) who provided their sex and age.  These countries were 96 
chosen because residents of these countries made up the majority (72.5%; for most countries 97 
less than 100 individuals participated), and the level of use for the illicit drugs we considered 98 
is similar across countries [26].  Further discussion of the design, utility, validity, and 99 
limitations of the GDS is available [11, 16-24].  Ethical approval was received from the Joint 100 
South London and Maudsley and Institute of Psychiatry NHS Research Ethics Committee.   101 
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2.2 - Measures 102 
2.2.1 - Past 12 month drug use   103 
LCA was used to identify of distinct patterns of self-reported illicit drug and non-104 
prescribed medication use in the previous 12 months.  Respondents were asked whether they 105 
had used each of an extensive list of drugs in the past 12 months; drug categories for which at 106 
least 10% of participants endorsed use were included.  Eight drugs were selected on this 107 
basis: 108 
• Cannabis (grass, skunk, resin, and oil) 109 
• Ecstasy (MDMA pills and powder) 110 
• Cocaine 111 
• Stimulants (dexamphetamine, methylamphetamine, and mephedrone) 112 
• Nitrous oxide 113 
• Ketamine (also including methoxetamine and N-ethylketamine) 114 
• Benzodiazepines (non-prescription use only) 115 
• Opioid Painkillers (non-prescription use only) 116 
2.2.2 - Predictors of class membership 117 
To test whether classes identified by LCA differed on other characteristics, we 118 
investigated whether class membership was associated with socio-demographic 119 
characteristics, tobacco and alcohol use, mental health diagnoses, and risk behaviours. 120 
Socio-demographic characteristics:  Gender and country of residence were used as reported.  121 
Age was collected as a continuous variable and then categorized.  Sexual orientation, living 122 
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situation, and highest educational qualification were derived directly from individual 123 
questions, with some categories collapsed due to small numbers (e.g. homosexual and 124 
bisexual orientation categories were combined).  Occupational status was derived from three 125 
questions on whether participants were working, studying, or unemployed, combined to 126 
categorize participants as studying only, studying and working, working only, or 127 
unemployed. 128 
Substance use:  Tobacco and alcohol use were defined as any use in the preceding 12 months.  129 
Hazardous alcohol use was assessed using the 10-item AUDIT questionnaire [27, 28].  130 
Participants were asked whether they wanted to use less of any of illicit or non-prescribed 131 
drugs they reported using.  Responses relating to drugs included in the LCA were combined 132 
to create an overall indicator of participant desire to use less of any drug. 133 
Mental health:  Participants were asked “Have you ever been diagnosed with a mental 134 
illness?” with responses combined in a single variable indicating depression, anxiety, or both 135 
(although other diagnoses could be recorded, few participants reported diagnoses other than 136 
anxiety and depression).  Personality disorder was screened for using the Standardised 137 
Assessment of Personality –	Abbreviated Scale (SAPAS), with a threshold of three used to 138 
indicate probable personality disorder [29, 30].   139 
High risk behaviour: Involvement in violent incidents was indexed by self-reported 140 
participation in a fight with another adult in the last 12 months.  Participants were then asked 141 
whether they had taken drugs (other than alcohol) prior to involvement in the incident.  These 142 
questions were combined to create a variable indicating whether participants had been 143 
involved in a violent incident, and if so whether they had taken drugs when it occurred.  144 
Sexual risk-taking was defined as having two or more sexual partners in the past year and not 145 
using condoms on all occasions of penetrative sex (as defined in [31]).  Participants were 146 
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asked to report emergency treatment due to any substances they endorsed use of; due to the 147 
low number of positive responses per drug, these were combined into a single variable 148 
indicating emergency treatment due to any illicit drug use. 149 
2.3 - Statistical analyses 150 
LCA identifies subgroups, or latent classes, within a sample using participant 151 
characteristics defined as categorical variables.  The aim is not to represent all possible 152 
combinations of characteristics but to identify the main patterns present, assuming some 153 
measurement error [32, 33].  For this study, this translates to identifying patterns of illicit 154 
drug and medication use based on reported past-year use of these substances.   155 
To find the likely number of subgroups, models postulating increasing numbers of 156 
latent classes were sequentially fitted, with identification of each model evaluated by refitting 157 
it using 100 sets of random starting values.  Models were considered identified if at least 80% 158 
of sets converged to the same solution [32, 33].  The best-fitting model was selected by 159 
examining the Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) 160 
for each model [34], and considering the size, distinctness, and ease of interpretation of the 161 
classes identified [33].  This was informed by the class membership probabilities, the 162 
estimated proportion of the sample belonging to each class, and the item-response 163 
probabilities for each class, which represent the likely values for the set of characteristics (i.e. 164 
probability of endorsing use of each substance), given membership of a particular class. 165 
Multinomial logistic regression models estimated via the “one-step” approach were 166 
used to explore associations between individual covariates and subgroup membership [35, 167 
36].  Coefficient estimates for each class were combined with the known distribution of each 168 
covariate to estimate the probability of each covariate value conditional on latent class 169 
membership.  Models including adjustments for sex, age, and country of residence were then 170 
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fitted for each socio-demographic, mental health, and risk behaviour variable to examine the 171 
adjusted associations with class membership.     172 
As this was an exploratory study without prior hypotheses regarding particular 173 
population subgroups, we did not fit grouped LCA models using, for example, sex or country 174 
of residence.  All tests were two-tailed but given the number of models fitted α=0.05 was not 175 
appropriate.  A Bonferroni corrected threshold would be P≤0.004, although we interpreted P-176 
values as measures of the strength of evidence for an association [37], rather than simply 177 
applying a threshold for statistical significance.  Analyses were conducted in R (version 3.0.2 178 
for Windows) using the LCCA package (version 1.1.0) [36]. 179 
3 - RESULTS 180 
3.1 - Sample character istics 181 
From the complete sample of 22,289 participants, we excluded 6,122 not resident in 182 
the three chosen countries.  A further 1,298 were excluded due to missing age and/or sex 183 
(524 missing both, 723 missing sex, 51 missing age), leaving 14,869 individuals.  Most 184 
participants were male (68.5%) and aged between 15 and 35 years (71.2%; Table 1).  The 185 
proportions of participants endorsing past year use of the selected drugs were: cannabis 186 
(64.0%), ecstasy (37.6%), cocaine (24.8%), stimulants (10.6%), nitrous (11.7%), ketamine 187 
(14.3%), benzodiazepines (10.5%), and opioid pain-killers (11.3%). 188 
3.2 - Latent class analysis of illicit drug use in previous 12 months 189 
3.2.1 - Model selection 190 
Eight latent class models (one to eight classes) were fitted but fit statistics did not 191 
unequivocally identify a best-fitting model (Supplementary Table 1).  This discordance is 192 
not uncommon as the AIC and BIC have different strengths, but the BIC generally selects 193 
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more parsimonious models and performs better for model selection in LCA of large samples 194 
[34].  The AIC was lowest for the eight-class model, but this model was not identified 195 
(Supplementary Figure 1).  In contrast, the BIC was lowest for the six-class model, which 196 
was identified as 98% of models had the same log-likelihood.  Examination of the item-197 
response probabilities confirmed that the subgroups identified in the six-class model had 198 
distinct characteristics (Figure 1 and Supplementary Table 2), and that no class was too 199 
small (smallest class contained 4% of the sample, approximately 621 participants).  These 200 
results indicated that the six-class model was most appropriate for these data. 201 
3.2.2 - Latent class model interpretation 202 
The item-response probabilities (Figure 1) suggest the classes defined by the six-class 203 
model can be characterised as follows: 204 
1. Non-polysubstance (49.1% of the sample): No polysubstance use - moderate 205 
probability of cannabis use only; 206 
2. Cannabis and ecstasy (23.6%): High probabilities of cannabis and ecstasy use, 207 
moderate probability of cocaine use; 208 
3. Illicit only (9.4%): High probabilities of using most illicit drugs, but particularly 209 
cannabis, ecstasy, and ketamine; 210 
4. Ecstasy and cocaine (8.3%): High probabilities of ecstasy and cocaine use, moderate 211 
probability of cannabis use; 212 
5. Cannabis and medication (5.9%): High/moderate probabilities of cannabis, 213 
benzodiazepine, and opioid pain-killer use; 214 
6. All substances (3.8%): High/moderate probabilities of using all drugs. 215 
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 There were two sets of drugs that appeared to be primarily used by the same 216 
subgroups of participants.  The two groups with moderate/high probabilities of endorsing 217 
ketamine use (illicit only and all substances) also had similar probabilities of endorsing 218 
nitrous oxide use (Supplementary Table 2).  Similarly, the two groups with moderate/high 219 
probabilities of endorsing benzodiazepine use (cannabis and medication, and all substances) 220 
also had moderate/high probabilities of endorsing opioid pain-killer use.  In contrast, the use 221 
of cannabis, ecstasy, cocaine, or stimulants did not display an association with use of another 222 
drug that was consistent across subgroups. 223 
3.3 - Latent class character istics 224 
Compared to the polysubstance classes, participants in the non-polysubstance class 225 
were more likely to be female, and less likely to use tobacco, desire to use drugs less, have 226 
received a diagnosis of anxiety/depression, or be involved in violence or sexual risk-taking 227 
(see Table 2).  They were also less likely to be in the 15-25 years age group compared to the 228 
polysubstance classes, with the exception of the ecstasy and cocaine class; only 7.4% of 229 
participants in this class were age 25 or younger.  There were no substantial differences in 230 
past year alcohol use or hazardous alcohol use.        231 
Participants in the cannabis and prescription medications class were more likely to 232 
report anxiety and/or depression diagnoses than members of any other class (29% compared 233 
to estimates between 11.1% and 19%), but less likely to report risky sexual behaviour (15.4% 234 
compared to estimates of 23.7% to 39.7%).  Participants most likely to report risky sexual 235 
behaviour were those in the two classes defined by moderate/high probability of use of all 236 
illicit drugs (only or with prescription medications; 39.7% and 37.4% respectively).  237 
Members of these classes were also the most likely to report involvement in violent incidents, 238 
regardless of illicit drug use. 239 
 240 
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3.4 – Associations with latent class membership 241 
Results from multinomial logistic regression models including adjustments for sex, 242 
age, and country of residence supported the majority of the associations with latent class 243 
membership suggested by the class characteristics (see Table 3).  Sexual orientation was only 244 
associated with membership of the ecstasy and cocaine, and cannabis and medication classes; 245 
identifying as non-heterosexual increased the odds of belonging to these classes around two-246 
fold.  Having a higher degree was associated with increased odds of belonging to all 247 
polysubstance classes except those defined by use of a broad range of illicit drugs (illicit only 248 
and all drugs).  Living alone increased the odds of membership of the illicit only, ecstasy and 249 
cocaine, and all drugs classes.  Past year and hazardous alcohol use were not associated with 250 
class membership, but past year tobacco use was, with the strongest association identified 251 
with the all substances class (OR 28.14, 95% CI 21.43-36.94).  This class also had the 252 
strongest association with reporting a desire to use drugs less (OR 70.11, 95% CI 37.7-253 
130.4).   254 
The adjusted multinomial logistic regression results for mental health diagnoses 255 
showed a positive association with membership of the cannabis and medication class but only 256 
for anxiety (OR 2.66, 95% CI 2.10-3.38), with similar results for personality disorder.  The 257 
results for involvement in violence differed after adjustment; a strong association was still 258 
identified with the all substances class, but violence without or with drugs was also 259 
associated with the cannabis and medications class (OR 1.82, 95% CI 1.24-2.65 and OR 260 
33.41, 95% CI 4.34-257.04 respectively).  Involvement in a violent incident with drugs was 261 
also associated with membership of the ecstasy and cocaine class.  Sexual risk-taking was 262 
positively associated with membership of all polysubstance classes, but particularly those 263 
defined by ecstasy and cocaine use (OR 4.41, 95% CI 3.57-5.43), and use of all drugs (OR 264 
5.79, 95% CI 4.66-7.18).   265 
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4 - DISCUSSION 266 
We characterised patterns of drug use in a large international sample with high levels 267 
of use, identifying five polysubstance use classes that collectively contained just over 50% of 268 
the sample and had distinct patterns of use that were more nuanced than a simple increase in 269 
the number of drugs used.  These polysubstance classes were primarily distinguished by 270 
differences in use of nitrous, ketamine, benzodiazepine, and opioid pain-killers, substances 271 
that have received limited attention in LCA of general population samples.  Strong 272 
associations with mental health and high-risk behaviours were identified for three of the five 273 
polysubstance classes: ecstasy and cocaine use, cannabis and medication use, and use of all 274 
drugs.   275 
The polysubstance subgroups identified in this sample, and their associations with 276 
mental health and risk behaviours, replicate some findings from previous studies using large, 277 
general population samples.  The subgroup characterised by cannabis and prescription 278 
medication use, and the association between this subgroup and mental illness that we 279 
identified, has also been found in studies from Australia and the USA [5, 6, 15].  An 280 
association between use of many illicit drugs and antisocial behaviour was also identified in 281 
these samples, although antisocial behaviour was characterised as conduct disorder and/or 282 
incarceration [5, 6].  The association between sexual risk-taking and polysubstance use has 283 
been identified in many settings [38].  Within the LCA literature, Connell et al. [39] 284 
identified a strong positive association between risky sexual behaviour by US adolescents 285 
and intensity of polysubstance use (alcohol, tobacco, cannabis, cocaine and inhalant use), 286 
while in adults a history of sexually transmitted infections predicted polysubstance use 287 
involving cannabis and cocaine [5].   288 
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We identified two sets of drugs which participants of certain subgroups endorsed use 289 
of to a similar level - benzodiazepines and opioid pain-killers, and nitrous oxide and ketamine 290 
– raising interesting questions about how and why individuals use these drugs.  Simultaneous 291 
use of benzodiazepines and opioid pain-killers to enhance drug effects for recreational 292 
purposes is well documented [40], but it is unclear whether this is also true for nitrous oxide 293 
and ketamine.  Both drugs are N-methyl-D-aspartate (NMDA)-antagonists and have medical 294 
uses as analgesics employed during anaesthesia [41, 42], so users could be substituting one 295 
for the other, or seeking to increase the overall effect by combining them.  As the potential 296 
for adverse events, such as drug overdose or respiratory depression, is increased by 297 
simultaneous use, particularly involving drugs from the same class [41, 42], further 298 
investigation of these drug combinations is needed. 299 
4.1 - Limitations 300 
The major limitations of this study relate to the GDS sampling strategy and the time-301 
frame of substance use.  The non-representative sampling method used precludes estimating 302 
the extent to which these results are representative of the populations of the countries 303 
included.  However, this strategy permitted recruitment of a large sample with high levels of 304 
substance use, facilitating a LCA that identified patterns of use that might have been 305 
overlooked in a representative general population sample.  As GDS is cross-sectional, we 306 
cannot make causal inferences about relationships between mental health, risk behaviours, 307 
and polysubstance use.  Additionally, we used data on 12-month drug use, which is not 308 
necessarily the same as simultaneous use during a small time window (e.g. 24-48 hours), 309 
although Quek et al. [9] found that most individuals reporting use of multiple drugs within a 310 
12-month period also reported simultaneous use of those drugs. 311 
 312 
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5 - CONCLUSIONS 313 
There are multiple, distinct patterns of polysubstance use involving illicit drugs and 314 
non-prescription use of medications that are more complex than a simple increase in the 315 
number of drugs used.  People engaged in these different patterns of use differ in terms of 316 
both sociodemographic characteristics, and mental health and risk-taking behaviours.  The 317 
clinical assessment and harm reduction implications of this work are potentially significant. 318 
Most health promotion and harm reduction activities focus on the acute intoxication-related 319 
consequences of using single drugs, but our work confirms the need to holistically address 320 
polysubstance use and drug use related activities.  Longitudinal research using representative 321 
samples is needed to unravel the temporal nature of these associations, and to determine 322 
whether longer-term trajectories of drug use and health differ between latent classes.  Further 323 
characterisation of simultaneous use of multiple drugs is also warranted, particularly relating 324 
to frequency of use, motivations for use, and possibilities for harm reduction.   325 
 326 
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TABLES		
Table 1: Demographic characteristics, mental health, and risk behaviours for the sample of 
14,869 participants.  Note that the “Missing” category is only shown for variables with 
missing data. 
 
 
Variable Values Number Percentage 
Sex Female 4685 31.5 
Age 15 - 25 years 6521 43.9 
 >25 - 35 years 4052 27.3 
 >35 - 45 years 2143 14.4 
 >45 years 2153 14.5 
Country of residence UK 5869 39.5 
 Australia 6313 42.5 
 USA 2687 18.1 
Sexual orientation Heterosexual 12006 80.7 
 Bi/Homosexual 2508 16.9 
 Missing 355 2.4 
Qualifications Higher degree 3038 20.4 
 Degree 4905 33.0 
 Trade/Diploma 1577 10.6 
 Senior high school 3471 23.3 
 Junior high school or less 1651 11.1 
 Missing 227 1.5 
Occupational status Working only 6784 45.6 
 Studying and working 3280 22.1 
 Studying only 2880 19.4 
 Unemployed 1356 9.1 
 Missing 569 3.8 
Living status Partner 5353 36.0 
 Shared housing 3841 25.8 
 Family members 3345 22.5 
 Alone 2024 13.6 
 Missing 306 2.1 
Tobacco use (last 12 months) Yes 7613 51.2 
Alcohol use (last 12 months) Yes 13809 92.9 
AUDIT score Hazardous 1975 13.3 
Desire to use drugs less Yes 2601 17.5 
Treatment for anxiety and/or depression No 11386 76.6 
 Anxiety 284 1.9 
 Depression 1283 8.6 
 Both 1443 9.7 
 Missing 473 3.2 
Personality disorder (SAPAS) No 6423 43.2 
 Yes 7915 53.2 
 Missing 531 3.6 
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Variable Values Number Percentage 
Involvement in violent incident No 13776 92.6 
 Yes, no drugs 836 5.6 
 Yes, with drugs 174 1.2 
 Missing 83 0.6 
Sexual risk-taking No 10767 72.4 
 Yes 2609 17.5 
 Missing 1493 10.0 
Emergency treatment Yes 73 0.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22	
Table 2: Characteristics of Global Drug Survey 2012 participants by polysubstance use class. 
 
Variable Category Non-
polysubstance 
Cannabis 
and 
ecstasy 
Illicit 
only 
Ecstasy 
and 
cocaine 
Cannabis 
and 
medication 
All 
drugs 
Sex Female 46.4 16.8 18.3 32.5 28.4 27.9 
Age 15 - 25 years 30.9 74.4 62.6 7.4 54.2 49.3 
 >25 - 35 years 33.5 12.4 18.2 45.0 22.3 24.6 
 >35 - 45 years 17.7 6.6 9.6 23.8 11.8 13.0 
 >45 years 17.8 6.6 9.7 23.9 11.8 13.1 
Country of 
residence Australia 38.6 42.3 69.5 48.6 23.3 43.6 
 USA 19.3 18.1 9.6 16.1 24.1 17.7 
 UK 42.1 39.6 20.9 35.2 52.6 38.7 
Sexual orientation Heterosexual 83.9 86.9 87.9 71.0 75.1 72.9 
Qualifications Higher Degree 15.1 25.4 19.6 14.1 24.0 20.5 
 Degree 51.6 18.5 37.3 54.9 23.1 34.2 
 Trade/Diploma 7.8 13.2 10.2 7.3 12.4 10.7 
 
Senior high 
school 17.3 29.0 22.3 16.1 27.4 23.4 
 
Junior high 
school or less 8.2 13.8 10.6 7.6 13.0 11.2 
Occupational 
status Working only 51.7 37.4 51.5 76.0 36.1 48.3 
 
Studying and 
working 21.1 27.3 21.2 10.5 27.9 22.6 
 Studying only 18.5 24.0 18.6 9.2 24.5 19.8 
 Unemployed 8.7 11.3 8.8 4.3 11.5 9.3 
Living status Partner 38.7 31.5 37.4 44.1 29.7 40.8 
 Shared housing 25.6 28.6 26.1 23.3 29.3 24.7 
 Family members 22.3 24.9 22.7 20.3 25.5 21.5 
 Alone 13.5 15.1 13.8 12.3 15.4 13.0 
Tobacco use Yes 18.5 69.7 86.3 45.3 75.0 84.5 
Alcohol use Yes 93.3 92.7 92.5 91.0 93.6 92.6 
AUDIT score Hazardous 13.5 13.2 14.6 10.8 15.6 9.1 
Desire to use 
drugs less Yes 2.0 24.5 37.0 28.3 21.2 52.6 
Diagnosed with 
anxiety and/or 
depression No 79.4 88.9 87.3 84.8 61.0 79.1 
 Anxiety 1.9 1.0 1.2 1.4 3.7 2.0 
 Depression 8.8 4.7 5.4 6.5 16.6 8.9 
 Both 9.9 5.3 6.1 7.3 18.7 10.0 
Personality 
disorder Yes 56.3 53.5 50.9 42.9 67.1 63.8 
Violent incident No 96.0 90.5 87.9 93.6 90.6 89.0 
 Yes, no drugs 3.3 7.9 10.0 5.3 7.8 9.1 
 Yes, with drugs 0.7 1.6 2.1 1.1 1.6 1.9 
Sexual risk-taking Yes 8.9 23.7 39.7 32.8 15.4 37.4 
Emergency 
treatment Yes 0.5 0.4 0.5 0.8 0.4 0.2 
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Table 3: Associations between latent class membership and participant characteristics, adjusted for sex, age, and country of residence.  N 
indicates the number of participants included in the analysis (due to missing data for covariate).  All results indicate a comparison with latent 
class 1 (Non-polysubstance).   
 
Variable Category Cannabis and ecstasy Illicit only Ecstasy and cocaine Cannabis and medication All drugs N 
  
OR CI P OR CI P OR CI P OR CI P OR CI P 
 Sexual 
orientation Heterosexual 1 
  
1 
  
1 
  
1 
  
1 
  
14514 
 
Bi/Homosexual 1.05 (0.87 - 1.26) 0.64 0.81 (0.65 - 1.01) 0.06 1.74 (1.45 - 2.09) <0.0001 2.08 (1.65 - 2.62) <0.0001 0.92 (0.71 - 1.2) 0.54 
 Qualifications Higher Degree 2.31 (1.94 - 2.75) <0.0001 1.09 (0.88 - 1.33) 0.43 1.58 (1.28 - 1.94) <0.0001 2.29 (1.81 - 2.89) <0.0001 1.01 (0.77 - 1.32) 0.96 14642 
 
Degree 1 
  
1 
  
1 
  
1 
  
1 
   
 
Trade/Diploma 0.93 (0.79 - 1.09) 0.38 0.84 (0.67 - 1.05) 0.13 1.13 (0.93 - 1.37) 0.21 1.14 (0.88 - 1.46) 0.31 0.73 (0.56 - 0.95) 0.02 
 
 
Senior high 
school 0.65 (0.56 - 0.77) <0.0001 0.55 (0.46 - 0.67) <0.0001 0.74 (0.61 - 0.89) 0.002 0.6 (0.47 - 0.77) 0.0001 0.43 (0.35 - 0.54) <0.0001 
 
 
Junior high 
school or less 1.27 (1.07 - 1.51) 0.005 0.91 (0.71 - 1.17) 0.46 1.26 (1.04 - 1.54) 0.02 1.28 (0.96 - 1.7) 0.09 1.18 (0.92 - 1.5) 0.20 
 Occupational 
status Working only 1 
  
1 
  
1 
  
1 
  
1 
  
14300 
 
Studying and 
working 1.38 (1.12 - 1.69) 0.0021 0.91 (0.7 - 1.18) 0.47 0.54 (0.44 - 0.66) <0.0001 2.11 (1.63 - 2.74) <0.0001 1.07 (0.81 - 1.42) 0.64 
 
 
Studying only 0.9 (0.74 - 1.09) 0.28 1.06 (0.84 - 1.34) 0.63 1.9 (1.44 - 2.51) <0.0001 1.19 (0.93 - 1.52) 0.16 1.58 (1.18 - 2.12) 0.002 
 
 
Unemployed 1.16 (1 - 1.36) 0.05 1.02 (0.86 - 1.21) 0.83 1.97 (1.44 - 2.72) <0.0001 1.4 (1.14 - 1.7) 0.001 1.47 (1.13 - 1.9) 0.004 
 Living status Partner 1 
  
1 
  
1 
  
1 
  
1 
  
14563 
 
Shared housing 1.27 (1.1 - 1.46) 0.001 1 (0.8 - 1.25) 0.98 0.96 (0.82 - 1.12) 0.58 1.3 (1.03 - 1.64) 0.03 0.98 (0.75 - 1.28) 0.86 
 
 
Family 
members 0.72 (0.61 - 0.86) 0.0002 0.59 (0.48 - 0.72) <0.0001 0.71 (0.58 - 0.87) 0.001 0.73 (0.57 - 0.94) 0.01 0.33 (0.26 - 0.43) <0.0001 
 
 
Alone 1.05 (0.91 - 1.21) 0.50 1.73 (1.49 - 2) <0.0001 2.2 (1.74 - 2.79) <0.0001 1.04 (0.85 - 1.26) 0.71 1.98 (1.66 - 2.35) <0.0001 
 Tobacco use No 1 
  
1 
  
1 
  
1 
  
1 
  
14869 
 
Yes 6.23 (5.12 - 7.58) <0.0001 11.49 (9.15 - 14.42) <0.0001 5.73 (4.8 - 6.85) <0.0001 18.02 
(13.72 - 
23.66) <0.0001 28.14 
(21.43 - 
36.94) <0.0001 
 Alcohol use No 1 
  
1 
  
1 
  
1 
  
1 
  
14869 
 
Yes 1.05 (0.79 - 1.38) 0.75 0.75 (0.57 - 1) 0.05 0.83 (0.64 - 1.08) 0.17 0.95 (0.64 - 1.4) 0.79 0.93 (0.66 - 1.3) 0.68 
 AUDIT score Non-hazardous 1 
  
1 
  
1 
  
1 
  
1 
  
14869 
 
Hazardous 1.03 (0.83 - 1.29) 0.77 1.12 (0.89 - 1.41) 0.35 0.81 (0.65 - 1) 0.06 1.18 (0.88 - 1.57) 0.27 0.66 (0.42 - 1.02) 0.06 
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Variable Category Cannabis and ecstasy Illicit only Ecstasy and cocaine Cannabis and medication All drugs N 
  
OR CI P OR CI P OR CI P OR CI P OR CI P 
 Desire to use 
drugs less No 1 
  
1 
  
1 
  
1 
  
1 
  
14869 
 
Yes 13.0 (7.0 - 24.21) <0.0001 26.37 (14.0 - 49.63) <0.0001 29.34 (16.2 - 53.13) <0.0001 26.77 
(14.13 - 
50.72) <0.0001 70.11 
(37.7 - 
130.4) <0.0001 
 Diagnosed 
with anxiety 
and/or 
depression No 1 
  
1 
  
1 
  
1 
  
1 
  
14396 
 
Anxiety 0.72 (0.56 - 0.92) 0.01 0.57 (0.41 - 0.8) 0.001 0.71 (0.55 - 0.9) 0.0055 2.66 (2.1 - 3.38) <0.0001 0.97 (0.72 - 1.31) 0.85 
 
 
Depression 1.09 (0.78 - 1.53) 0.62 1.19 (0.72 - 1.96) 0.50 1.24 (0.86 - 1.79) 0.26 0.92 (0.64 - 1.32) 0.63 0.65 (0.44 - 0.94) 0.02 
 
 
Both 0.81 (0.53 - 1.22) 0.31 0.5 (0.27 - 0.94) 0.03 0.55 (0.34 - 0.87) 0.01 0.95 (0.6 - 1.5) 0.81 1.12 (0.71 - 1.78) 0.62 
 Personality 
disorder No 1 
  
1 
  
1 
  
1 
  
1 
  
14338 
 
Yes 1.01 (0.87 - 1.17) 0.90 0.74 (0.63 - 0.87) 0.0002 0.74 (0.64 - 0.85) <0.0001 1.37 (1.12 - 1.69) 0.0026 0.84 (0.7 - 1) 0.05 
 Violent 
incident No 1 
  
1 
  
1 
  
1 
  
1 
  
14786 
 
Yes, no drugs 1.05 (0.75 - 1.47) 0.77 1.6 (1.16 - 2.19) 0.0037 1.44 (0.97 - 2.12) 0.07 1.82 (1.24 - 2.65) 0.002 1.9 (1.36 - 2.64) 0.0001 
 
 
Yes, with 
drugs 6.57 (0.68 - 63.2) 0.10 2.75 (0.22 - 34.05) 0.43 26.33 (3.89 - 178.1) 0.0008 33.41 (4.3 - 257.0) 0.0007 22.07 (2.8 - 172.8) 0.0032 
 Sexual risk-
taking No 1 
  
1 
  
1 
  
1 
  
1 
  
13376 
 
Yes 1.48 (1.19 - 1.83) 0.0004 3.21 (2.55 - 4.03) <0.0001 4.41 (3.57 - 5.43) <0.0001 2.23 (1.7 - 2.93) <0.0001 5.79 (4.66 - 7.18) <0.0001 
 Emergency 
treatment No 1 
  
1 
  
1 
  
1 
  
1 
  
14869 
 
Yes 1.15 (0.45 - 2.93) 0.77 0.71 (0.19 - 2.75) 0.62 1.36 (0.59 - 3.15) 0.47 0.29 (0.04 - 2.31) 0.24 1.41 (0.48 - 4.18) 0.53 
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FIGURES	
	
Figure 1: Item response probabilities (for positive endorsement of use in the last 12 months) with standard errors by latent class for the six-class 
model.  The classes are labelled as follows: Class 1 indicates non-polysubstance; Class 2 cannabis and ecstasy; Class 3 illicit drugs only; Class 4 
ecstasy and cocaine; Class 5 cannabis and medication; Class 6 indicates all drugs.  Classes are shown in decreasing order of class membership 
probability, as per Supplementary Table 2. 
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SUPPLEMENTARY	TABLES	AND	FIGURES		
Supplementary Table 1: Model fitting statistics for the ten models postulating different numbers of latent classes.  BIC indicates Bayesian 
information criterion; AIC indicates Akaike information criterion.  Best-fitting models according to each indicator are shown in bold. 
 
Classes Log-likelihood BIC AIC 
1 -54519.6 109116.0 109055.1 
2 -48614.3 97391.8 97262.5 
3 -48080.9 96411.6 96213.9 
4 -47697.8 95731.9 95465.6 
5 -47629.3 95681.2 95346.5 
6 -47538.8 95586.8 95183.7 
7 -47514.4 95624.5 95152.9 
8 -47499.4 95680.9 95140.8 
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Supplementary Figure 1: Results of model identification evaluation.  Each panel displays the results for a model with the specified number of 
classes.  Log-likelihood values are graphed for 100 models fitted from different starting values for each latent class model.  The red horizontal 
line indicates the threshold of 80%. 
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Supplementary Table 2: Estimates and standard errors for class membership probabilities and item response probabilities (probability of 
endorsing substance use) from six-class latent class model for illicit and prescription drug use in the previous 12 months. 
Probability Drug Non-
polysubstance 
Cannabis and 
ecstasy 
Illicit only Ecstasy and 
cocaine 
Cannabis and 
medication 
All drugs 
  
Estimate S.E. Estimate S.E. Estimate S.E. Estimate S.E. Estimate S.E. Estimate S.E. 
Class membership 
 
0.49 0.01 0.24 0.02 0.10 0.01 0.08 0.02 0.06 0.01 0.04 0.01 
             
Item response Cannabis 0.42 0.01 0.93 0.03 0.92 0.02 0.60 0.06 0.83 0.02 0.95 0.01 
 
Ecstasy 0.01 0.01 0.63 0.04 0.99 0.01 0.82 0.04 0.38 0.05 0.96 0.02 
 
Cocaine 0.03 0.00 0.28 0.03 0.64 0.02 0.75 0.06 0.26 0.03 0.78 0.03 
 
Stimulants 0.01 0.00 0.09 0.01 0.32 0.02 0.23 0.03 0.21 0.02 0.51 0.04 
 
Nitrous 0.01 0.00 0.12 0.01 0.53 0.03 0.05 0.02 0.17 0.02 0.48 0.03 
 
Ketamine 0.03 0.00 0.07 0.01 0.72 0.04 0.19 0.04 0.08 0.02 0.58 0.04 
 
Benzodiazepines 0.02 0.00 0.03 0.01 0.20 0.03 0.11 0.02 0.61 0.06 0.69 0.05 
 
Opioid Painkiller 0.05 0.00 0.06 0.01 0.04 0.03 0.04 0.02 0.61 0.06 0.76 0.09 
	
	
 
 
